Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 16th October 2018
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Dopharma to acquire Boehringer Ingelheim production site
The move follows the presentation of Boehringer’s animal health strategic orientations.

Sale of Saint-Herblon site expected to complete in early 2019

Boehringer Ingelheim has announced the sale of its production site in Saint-Herblon, France, to Dutch company Dopharma.

First announced in October last year, the move follows the presentation of Boehringer’s animal health strategic orientations.

The group confirmed its strategy to focus on advanced and preventative healthcare; Saint-Herblon mainly produces generics and antibiotics for livestock.

Dopharma is an independent, family-owned company that develops, produces and distributes veterinary products for livestock.

Erick Lelouche, president of Boehringer Ingelheim Animal Health in France, said: “I am convinced that this project will offer a solid foundation for the future to the site and its employees. Indeed, we will collaborate with Dopharma Saint-Herblon that will produce some of our specialized products during the coming years.”

The sale is expected to complete by the end of the first quarter of 2019, after the legal and consultation process is finalised.

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'